Literature DB >> 26648608

Fluticasone furoate with vilanterol.

.   

Abstract

Entities:  

Year:  2014        PMID： 26648608      PMCID： PMC4654045          DOI： 10.18773/austprescr.2015.011

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  7 in total

1.  Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.

Authors:  Fernando J Martinez; Joseph Boscia; Gregory Feldman; Catherine Scott-Wilson; Sally Kilbride; Leonardo Fabbri; Courtney Crim; Peter M A Calverley
Journal:  Respir Med       Date:  2013-01-16       Impact factor: 3.415

2.  A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.

Authors:  Edward M Kerwin; Catherine Scott-Wilson; Lisa Sanford; Stephen Rennard; Alvar Agusti; Neil Barnes; Courtney Crim
Journal:  Respir Med       Date:  2013-01-23       Impact factor: 3.415

3.  Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

Authors:  Mark T Dransfield; Jean Bourbeau; Paul W Jones; Nicola A Hanania; Donald A Mahler; Jørgen Vestbo; Andrew Wachtel; Fernando J Martinez; Frank Barnhart; Lisa Sanford; Sally Lettis; Courtney Crim; Peter M A Calverley
Journal:  Lancet Respir Med       Date:  2013-04-12       Impact factor: 30.700

4.  Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.

Authors:  Eric D Bateman; Paul M O'Byrne; William W Busse; Jan Lötvall; Eugene R Bleecker; Leslie Andersen; Loretta Jacques; Lucy Frith; Jessica Lim; Ashley Woodcock
Journal:  Thorax       Date:  2013-11-19       Impact factor: 9.139

5.  Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.

Authors:  William W Busse; Paul M O'Byrne; Eugene R Bleecker; Jan Lötvall; Ashley Woodcock; Leslie Andersen; Wesley Hicks; Jodie Crawford; Loretta Jacques; Ludovic Apoux; Eric D Bateman
Journal:  Thorax       Date:  2013-02-25       Impact factor: 9.139

6.  Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma.

Authors:  Paul M O'Byrne; Eugene R Bleecker; Eric D Bateman; William W Busse; Ashley Woodcock; Richard Forth; William T Toler; Loretta Jacques; Jan Lötvall
Journal:  Eur Respir J       Date:  2013-10-17       Impact factor: 16.671

7.  Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial.

Authors:  Ashley Woodcock; Eugene R Bleecker; Jan Lötvall; Paul M O'Byrne; Eric D Bateman; Hilary Medley; Anna Ellsworth; Loretta Jacques; William W Busse
Journal:  Chest       Date:  2013-10       Impact factor: 9.410
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.